GLPG vs IONS vs LLY vs ALNY vs REGN

For growth investors, Galapagos N.

V. (GLPG) is the stronger pick with 303. 5% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Galapagos N. V. (GLPG) offers the better valuation at 4. 9x trailing P/E, making it the more compelling value choice. Analysts rate Ionis Pharmaceuticals, Inc. (IONS) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Galapagos N.

V. (GLPG) is the cheapest at 4. 9x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 15. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 0. 91x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to -63. 0% for Galapagos N. V. (GLPG). Over 10 years, the gap is even starker: LLY returned +1203% versus GLPG's -40. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 51β versus Regeneron Pharmaceuticals, Inc. 's 0. 77β — meaning REGN is approximately 51% more volatile than IONS relative to the S&P 500. On balance sheet safety, Galapagos N. V. (GLPG) carries a lower debt/equity ratio of 0% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Galapagos N.

V. (GLPG) is pulling ahead at 303. 5% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Galapagos N. V. grew EPS 333. 0% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, GLPG leads at 66. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -40. 5% for IONS. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 0. 91x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 15. 3x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 24. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 50. 6% to $445. 67.

In this comparison, LLY (0.

6% yield), REGN (0. 5% yield) pay a dividend. GLPG, IONS, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Both have compounded well over 10 years (LLY: +1203%, GLPG: -40. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLPG is a small-cap high-growth stock; IONS is a mid-cap high-growth stock; LLY is a large-cap high-growth stock; ALNY is a mid-cap high-growth stock; REGN is a mid-cap deep-value stock. LLY pays a dividend while GLPG, IONS, ALNY, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.